A Phase 1/2 interventional study of Bee Venom (BV) in Hemodialysis, Inflammation and Regulatory T Cell, sponsored by Mansoura University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Mansoura University · Phase 1/2, Interventional, and Other
Chronic kidney disease (CKD) has emerged asa major cause of morbidity and mortality world-wide. Advanced CKD results in accelerated cardiovascular disease, cachexia,anemia, andnumerous other complicationswhich impair thequalityof life and shorten the life span in this population Our study aims to investigate the effect of Bee venom on T Regulatory Cells and inflammation in hemodialysis patients. This study will be carried out on (60) hemodialysis patients attending Urology and Nephrology center (Mansoura university).
A prospective randomized control study. Patients will be devided in to two groups A. study group (20 patients) will receive bee venom. B. control group (40 patients): will not receive bee venom. All patients will be maintained on their regular medications eg: erythropoietin, iron, multivitamins, antihypertensive agents, and phosphate binders if needed.
3,536 studies on the registry are indexed under Inflammation; 642 are open to participants now.
This study's enrollment of 60 is above the median of 50 across 2,577 interventional studies indexed under Inflammation.
Browse Inflammation studies →Mansoura University is the lead sponsor of 1,119 studies on the registry; 183 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Bee Venom (BV)
subcutaneous injection of Bee venom in the study group
measurement of the effect of bee venom on T-regulatory cells
Time frame: 6 months
measurement of highly sensitive CRP
Time frame: 6 months
Plan to share: No
Ran from Jun 2024 to primary completion in Nov 2024, 5 months.
Of 40 non-industry phase 1/2 interventional studies under Inflammation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 62. This study's 5 months is below that.
Counting every sponsor, half of 46 studies reached it within 29 months; a quarter within 13 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bee Venoms